The approval was granted on July 14, 2026, underlining the company’s regulatory clearance for the active pharmaceutical ingredient (API) product in China.
“This approval is in addition to the valid Certificate of Suitability (CEP) already held by the company for Clopidogrel Bisulfate, further strengthening the Company’s regulatory portfolio and expanding its access to the Chinese pharmaceutical market,” it said.
ALSO READ | IOL Chemicals shares hit upper circuit after promoter raises stake in the June quarter
What is Clopidogrel Bisulfate API?
Clopidogrel Bisulfate API is the Active Pharmaceutical Ingredient (API) used in the production of medicines containing clopidogrel. Clopidogrel Bisulfate is the chemical form of clopidogrel used by pharmaceutical companies for making finished dosage medicines.
Clopidogrel is an antiplatelet medication that helps prevent blood clot formation by reducing the ability of platelets in the blood to stick together. It is used in medicines prescribed to help reduce the risk of clot-related cardiovascular events such as heart attacks and strokes.
Fourth Quarter Results
The company posted a consolidated net profit of ₹31.42 crore in the last quarter of FY25, up from ₹27.6 crore in the same period last year.
ALSO READ | IOL Chemicals reports minor fire incident at Minoxidil manufacturing unit in Punjab
Revenue from operations grew 4.7% to ₹527.7 crore, compared to ₹503.9 crore in the year-ago quarter. The company also saw a sharp 28.5% jump in EBITDA, which rose to ₹62.6 crore from ₹48.7 crore, supported by better cost management and product mix optimisation. Operating margins improved significantly to 11.8%, up from 9.6% in Q4FY24.
The robust margin expansion suggests continued traction in the company’s pharmaceutical and specialty chemicals businesses, which form the core of its revenue streams.
Shares of IOL Chemicals and Pharmaceuticals Ltd ended at ₹174.55, up by ₹4.80, or 2.83%, on the BSE.
ALSO READ | IOL Chem Q2 Results | Net profit jumps 56%, revenue up 8%, margins improve
